Research Analysts Issue Forecasts for ASMB FY2029 Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Assembly Biosciences in a research report issued on Monday, March 24th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical company will earn ($12.58) per share for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share.

Several other brokerages have also commented on ASMB. StockNews.com lowered shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Monday. Guggenheim assumed coverage on Assembly Biosciences in a report on Tuesday. They set a “buy” rating and a $31.00 price objective for the company.

Assembly Biosciences Price Performance

Shares of ASMB stock opened at $11.42 on Tuesday. The firm’s 50-day simple moving average is $12.77 and its 200-day simple moving average is $15.05. Assembly Biosciences has a 1-year low of $10.27 and a 1-year high of $19.93. The firm has a market cap of $72.59 million, a P/E ratio of -1.70 and a beta of 0.62.

Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, topping the consensus estimate of ($1.75) by $0.18. The firm had revenue of $7.36 million for the quarter, compared to the consensus estimate of $7.05 million. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Man Group plc acquired a new stake in shares of Assembly Biosciences in the fourth quarter valued at about $309,000. B Group Inc. acquired a new stake in Assembly Biosciences in the fourth quarter valued at approximately $799,000. Gilead Sciences Inc. acquired a new stake in Assembly Biosciences in the fourth quarter valued at approximately $34,865,000. Marshall Wace LLP raised its stake in shares of Assembly Biosciences by 16.5% during the fourth quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 2,098 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Assembly Biosciences by 44.3% during the fourth quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company’s stock worth $1,495,000 after purchasing an additional 29,087 shares in the last quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

Insider Transactions at Assembly Biosciences

In other Assembly Biosciences news, Director Michael Houghton bought 3,202 shares of Assembly Biosciences stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average price of $15.61 per share, for a total transaction of $49,983.22. Following the acquisition, the director now owns 3,202 shares of the company’s stock, valued at $49,983.22. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 5.10% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.